Medically reviewed
Ozempic is a GLP-1 receptor agonist approved for type 2 diabetes (ozempic). Evidence is from FDA prescribing information and peer-reviewed trials.
Ozempic is a GLP-1 receptor agonist used for Type 2 diabetes (Ozempic) and Chronic weight management (Wegovy).
Mechanism of action
Last Revised — by Dr. Jane Novak, MD, MPH
Class
GLP-1 RA
Active ingredient
Forms
Inj. + oral
Wegovy / Ozempic / Rybelsus
Avg loss
~15%
68 wks at 2.4 mg
Compounded
$99-249
/month telehealth
Pick your plan tier + deductible status for a tier-average estimate. Tap to expand.
Coverage explainer
Your PBM (pharmacy benefit manager), not your insurer, decides Ozempic formulary placement. OptumRx dropped Zepbound from its Premium formulary in July 2025 — CVS Caremark and Express Scripts kept both drugs on. See which PBM administers your plan and what the current stance is:
Read the PBM formulary teardown →Check Ozempic against another medication
Already taking something else? Look up interactions.
Type a medication you currently take. We'll route you to the full interaction report — and you should still confirm with your prescriber before changing anything.
Powered by FDA prescribing information cross-references. Not medical advice — for anything serious, call your prescriber or 911.
Supply normal · as of 2026-05-01
This is general drug information, not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication.
FDA supply status
Partial shortageReason: Demand increase for the drug
Limited: 0.25 mg/0.5 mL pen, 0.5 mg/0.5 mL pen
Expected resolution: Q3 2026 (per manufacturer guidance)
Last verified May 15, 2026. Source: FDA Drug Shortage Database.
Why is Ozempic prescribed?
Ozempic is FDA-approved to treat:
- Type 2 diabetes (Ozempic)
- Chronic weight management (Wegovy)
Dosing schedule
FDA-label titration timeline for Ozempic. Doses ramp gradually to limit gastrointestinal side effects; never accelerate the schedule without prescriber input.
Step 1
Weeks 1–4
0.25 mg
Step 2
Weeks 5–8
0.5 mg
Step 3
Weeks 9–12
1.0 mg
Step 4
Weeks 13–16
1.7 mg
Step 5
Week 17+
2.4 mg
Maintenance
Source: FDA prescribing information. Weekly subcutaneous injection. Dose escalation may be delayed if side effects are intolerable. Doses listed here are typical; your prescriber may adjust based on tolerance and response.
Titration schedule
Weekly dose progression
Each escalation holds 4 weeks before the next step up — standard pattern across GLP-1 weight-management labels.
Clinical trial results
Body-weight outcomes from the pivotal trials that anchor FDA approval. Each chart plots the active arm against the placebo or head-to-head comparator, week by week.
STEP-1
Semaglutide 2.4 mg subcutaneous weekly
Percentage change in body weight from baseline to week 68
- Duration
- 68 wk
- Active arm
- n=1,306
- Placebo arm
- n=655
- Final delta
- -14.9%
Key takeaways
- Mean body-weight loss at week 68 was -14.9% on semaglutide vs -2.4% on placebo.
- 86.4% of semaglutide participants achieved ≥5% weight loss; 69.1% achieved ≥10%.
- GI adverse events (nausea, diarrhea, vomiting, constipation) were the most common — usually mild-to-moderate and dose-titration related.
SUSTAIN-7
Semaglutide 1.0 mg subcutaneous weekly (vs dulaglutide 1.5 mg)
A1C change from baseline at week 40
- Duration
- 40 wk
- Active arm
- n=301
- Placebo arm
- n=299
- Final delta
- -6.5%
Key takeaways
- Head-to-head with dulaglutide 1.5 mg in T2D: semaglutide-1 produced -6.5% body-weight change vs -3.0% with dulaglutide.
- A1C reduction was -1.8% with semaglutide-1 vs -1.4% with dulaglutide; superiority confirmed.
- Gastrointestinal events were the most common reason for discontinuation in both arms.
Side effects by frequency
Incidence rates for Ozempic from the FDA prescribing information and pivotal trials. Numbers are active arm vs. placebo — the gap tells you how much of an effect is drug-caused vs. background.
- moderateNauseaGastrointestinal
- Active arm
- 44.2%
- Placebo
- 16.1%
Excess vs placebo: +28.1 pp
- moderateDiarrheaGastrointestinal
- Active arm
- 31.5%
- Placebo
- 15.9%
Excess vs placebo: +15.6 pp
- moderateVomitingGastrointestinal
- Active arm
- 24.8%
- Placebo
- 6.6%
Excess vs placebo: +18.2 pp
- mildConstipationGastrointestinal
- Active arm
- 23.4%
- Placebo
- 9.5%
Excess vs placebo: +13.9 pp
- mildAbdominal painGastrointestinal
- Active arm
- 20.2%
- Placebo
- 10.4%
Excess vs placebo: +9.8 pp
- mildHeadacheNervous system
- Active arm
- 14.6%
- Placebo
- 12.0%
Excess vs placebo: +2.6 pp
- mildFatigueGeneral / fatigue
- Active arm
- 11.0%
- Placebo
- 4.7%
Excess vs placebo: +6.3 pp
- severeGallbladder disorderLiver & gallbladder
- Active arm
- 2.6%
- Placebo
- 1.2%
Excess vs placebo: +1.4 pp
- severeAcute pancreatitisGastrointestinal
- Active arm
- 0.2%
- Placebo
- 0.1%
Excess vs placebo: +0.1 pp
"Excess vs placebo" is the percentage-point difference between active treatment and placebo arms. A small excess (e.g., headache at +2.6 pp) suggests the side effect is mostly background noise, not drug-caused. A large excess (e.g., nausea at +28 pp) is a strong drug signal.
Sources
- STEP-1 (Wilding et al., NEJM 2021)
Trial percentages are population averages. Your individual experience may differ. Severity labels reflect typical clinical impact, not how it will feel for any specific patient.
Use & safety
Pregnancy
C — Discontinue at least 2 months before a planned pregnancy due to long half-life.
Breastfeeding
Not recommended while breastfeeding. Animal data shows transfer into milk; human data limited.
Missed dose
If within 5 days of scheduled dose: take as soon as remembered, then continue normal weekly schedule. If more than 5 days late: skip the missed dose and resume the next scheduled dose.
Storage
Refrigerate 36-46°F (2-8°C) before first use. After first use, may be stored at room temperature 59-86°F (15-30°C) for up to 56 days. Protect from light. Do not freeze.
What Ozempic costs in 2026
From $199/mo via telehealth80% off retail
Average retail in the US: $998/month. We compare 4 pricing paths below so you can see exactly where the savings come from.
| Pricing path | Monthly cost |
|---|---|
Retail pharmacy Cash, no insurance, no coupon | $998 |
GoodRx coupon Same pharmacy, public coupon | $997 |
Commercial insurance Typical copay (median) | $25 |
Hims & Hers (compounded) Cheapest editorially-vetted path | $199 80% off retail |
RxNorm Code: 1991302
Conditions it treats
FDA-approved or commonly prescribed off-label for these conditions.
Type 2 diabetes(T2D)
Type 2 diabetes is a chronic condition in which the body either resists insulin or does not produce enough of it to maintain normal blood glucose. GLP-1 receptor agonists are recommended injectable add-on therapy when A1C target is not met on metformin, and lower A1C by 1.0-2.0 percentage points on average.
Learn about Type 2 diabetesObesity
Obesity is a chronic, relapsing disease defined by excess body fat that increases health risk. The medical threshold is BMI ≥30, or ≥27 with a weight-related comorbidity. GLP-1 medications Wegovy and Zepbound are FDA-approved for chronic weight management and produce 14–21% mean weight loss in clinical trials.
Learn about ObesityNAFLD / MASH(NAFLD)
Non-alcoholic fatty liver disease (NAFLD), now often called metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common chronic liver disease in the US. The progressive inflammatory form (MASH, formerly NASH) can lead to cirrhosis. GLP-1 medications show emerging benefit for both weight loss and direct liver effects.
Learn about NAFLD / MASHMore on Ozempic
Reader reviews
Verified user experiences with Ozempic. Reviews are moderated before publishing.
No user reviews yet
Be the first to share what worked — side effects, titration experience, dosing, weight-loss timeline. The form below takes ~2 minutes.
Sources & further reading
All clinical claims on this page are sourced from the FDA prescribing information and peer-reviewed literature. Verify the most current label before clinical decisions.
- FDA prescribing information for Ozempicaccessdata.fda.gov (opens in a new tab)
- DailyMed structured label (semaglutide)dailymed.nlm.nih.gov (opens in a new tab)
- Peer-reviewed trials & meta-analyses (semaglutide)pubmed.ncbi.nlm.nih.gov (opens in a new tab)
- Manufacturer page — Novo Nordiskmanufacturer site (opens in a new tab)
See our data sources of truth and the consolidated references bibliography for every claim cited above.
Related medications
Other drugs in the same class — GLP-1 receptor agonist.
Side-effect timeline
peaks fade
Typical 16-week titration schedule. Individual experience varies — track yours with the printable tracker.
- 1
Wk 1-2
First injection
- NauseaModerate
- FatigueModerate
- BloatingMild
Peak nausea — eat small protein-forward meals; hydrate.
- 2
Wk 3-4
Body adapting
- NauseaMild
- ConstipationModerate
- RefluxMild
Constipation climbs as GI motility slows. Add fiber + magnesium.
- 3
Wk 5-8
Dose escalation #1
- NauseaModerate
- FatigueMild
- DiarrheaMild
Symptoms re-spike for ~7 days after each escalation.
- 4
Wk 9-12
Settling in
- NauseaMild
- RefluxMild
GI complaints meaningfully fade. Weight loss accelerates.
- 5
Wk 13-16
Maintenance ramp
- Mild fatigueMild
- Hair sheddingMild
Hair shedding from rapid weight loss may appear (resolves by month 6).
- 6
Wk 17+
Maintenance
- Generally well-toleratedNone
Most side effects resolved. Watch for gallbladder symptoms long-term.
Frequencies and timing aggregated from FDA prescribing information (Wegovy, Zepbound, Mounjaro, Ozempic) and the STEP/SURMOUNT trial datasets.
12-month cost tracker
Compounded semaglutide (1 mg/mL, 3 mL vial)
Average US retail pharmacy price, per month. Hand-curated; updated monthly.
Cash price fell 35% over the past year
- Dec 25: FDA shortage list update tightened access; surviving compounders cut prices to retain volume
Prices reflect average list at major US pharmacies (CVS, Walgreens, Walmart). Your actual cost depends on insurance, pharmacy choice, and savings-card eligibility.
Where to get a prescription
Top providers prescribing Ozempic
Ranked by our editorial team. All accept new patients, ship 50-state, and use licensed US prescribers. Pricing reflects starting monthly cost as of 2026-05.
- 1Ro Top pick
Direct-to-consumer GLP-1 program with broad medication selection and a polished app.
- 500K+ patients
- ·
- 9 yrs in business
- ·
- Featured in NYT, Forbes, CNBC
From $99.00/mo4.40 ratingSave ~$10,782.96/yr vs cash list price
Best for brand-nameVisit RoWhy we picked it: Handles prior auth + appeals for commercial insurance — heavy lifting taken care of.
- 2LifeMD Insurance
Full primary-care telehealth with GLP-1 — the pick for patients who want ongoing PCP integration.
From $249.00/mo4.30 rating~3 hr· self-reportedSave ~$8,982.96/yr vs cash list price
- 3
Compounded-first GLP-1 telehealth with three-tier pricing — the cash-only value pick.
From $179.00/mo4.20 rating~1.5 hr· self-reported- LegitScript
Save ~$9,822.96/yr vs cash list price
Best for fast startVisit Henry MedsWhy we picked it: Same-week first dose for most US states; brand + compounded both available.
Sponsored partnerships. We earn commission when readers sign up. Editorial ranking is independent — full methodology at /how-we-rank.
GLP-1 receptor agonist alternatives
6 ways to save
Ways to actually pay less for this medication
Stacking two of these typically cuts more than a single savings card alone. Eligibility is program-specific; every link goes to the official source so you can verify.
Manufacturer savings card
Novo Nordisk's Wegovy Savings Offer and Lilly's Zepbound Savings Card reduce commercially-insured patients' copays. Eligibility excludes Medicare / Medicaid / Tricare. Terms and dollar amounts change quarterly — confirm on the brand site before signup.
Open program page →Verified 2026-06-01
HSA or FSA
GLP-1 medications prescribed for an IRS-qualified condition (T2D / chronic weight management with prescriber documentation) are eligible for HSA / FSA reimbursement. Use pre-tax dollars; save your invoices for substantiation.
Open tool →Verified 2026-06-01
Patient-assistance programs
Novo Nordisk PAP and Lilly Cares offer drug at no or reduced cost to qualified uninsured / underinsured patients. Income-tested; clinician submits the form. Approval windows are 30-90 days.
Open program page →Verified 2026-06-01
Medicare Extra Help (LIS)
Federal Medicare law has historically excluded weight-loss agents; 2024 CMS rulemaking is evolving. For T2D indications (Ozempic, Mounjaro, Rybelsus) Extra Help can cover most cost when the drug is on your Part D formulary. Check Medicare.gov for current status.
Open program page →Verified 2026-06-01
Tax deduction angle
Out-of-pocket prescription costs exceeding 7.5% of adjusted gross income are deductible on Schedule A. Save every receipt; pair with HSA for the strongest tax stack. Talk to a tax professional for your situation.
Open program page →Verified 2026-06-01
Cheapest cash-pay channel
Telehealth providers' cash-pay tiers (compounded routes; brand via savings card) routinely beat retail pharmacy cash. Compare current monthly cost on our ranking — prices updated monthly.
Open tool →Verified 2026-06-01
Editorial: we earn no commission on government-program signups. Cash-pay channel links use tracked /go redirects to affiliated telehealth providers — see disclosure. Savings-program terms change frequently — confirm dollar amounts and eligibility on each official page before signup. Each card shows the last date our editorial team confirmed the link.
Your first month on Ozempic, day by day
Editorial composite — your prescriber's protocol may differ. Individual timelines vary; call your prescriber if symptoms intensify rather than ease.
Days 1-3
First injection, mild appetite shift
Most patients notice subtler hunger cues within 48-72 hours. Some experience mild nausea — eat smaller, lower-fat meals; hydrate consistently.
Days 4-7
Side effects peak then ease
Mild GI side effects (nausea, soft stool, fatigue) typically peak around day 4-5 then settle. If they intensify, contact your prescriber before stepping up.
Weeks 2-4
Steady dose, adapting body
You stay at the starter dose for 4 weeks before the first step-up. Hunger and cravings continue declining; energy normalizes for most.
Week 5+
First dose escalation
Your prescriber steps you up to the next dose tier per the FDA label. Expect a brief return of GI side effects for 3-7 days as your body re-adapts.
Month 2+
Therapeutic dose territory
By week 9 most patients reach a therapeutic dose. Visible weight change usually appears 4-6 weeks after this point. Track progress monthly; do not weigh daily.
Your prescriber may slow any step where side effects are still settling. See the FDA label for the official titration schedule for Ozempic.
What you're paying for
What's typically included in a Ozempic telehealth subscription
Editorial composite across affiliated providers. Per-provider breakdowns live on each provider page — terms vary.
Licensed clinician visit
Initial asynchronous or video consult with a clinician licensed in your state. Eligibility, dosing, and any contraindications reviewed against your intake.
Medication, shipped
Brand or compounded GLP-1 prescription dispensed by a US-licensed pharmacy and shipped temperature-controlled to your address.
Ongoing care messaging
Async clinician messaging for side-effect management, dose-step questions, and refill timing. Most providers respond within one business day.
Refills + cost adjustments
Automatic refill scheduling tied to your dose cadence; price re-priced monthly when manufacturer programs or program tiers change.
Lab work, consult re-runs, and certain tier upgrades may incur additional cost depending on provider — confirm on the provider page before signup.
Real questions from Ozempic readers, clinician-answered
Pulled from our /q-and-a corpus by topical match. Every answer is written by a licensed clinician on staff.
Wegovy vs Zepbound — which one actually loses more weight?
Head-to-head SURMOUNT-5 (NEJM 2024) put max-dose tirzepatide (Zepbound) at 20.2% mean weight loss over 72 weeks vs 13.7% for max-dose semaglutide (Wegovy) — a 6.5-point gap. Zepbound patients also hit ≥15% loss at nearly twice the rate. Trade-off: tirzepatide GI side effects are slightly higher at max dose, and supply/pricing has been less stable. For most patients starting fresh, Zepbound is the higher-efficacy pick; Wegovy remains the choice if your insurance covers it and Zepbound is not on formulary.
Full answer
What if my insurance denies Wegovy?
Three paths: (1) appeal with documentation of BMI ≥30 (or ≥27 + comorbidity) and a prior lifestyle-intervention attempt — about 40% of denials reverse on appeal; (2) use the Novo WegovyCare savings card to drop cost to $499/mo; (3) switch to compounded semaglutide via a telehealth provider, $99-249/mo. Our /tools/insurance-coverage-checker shows what your plan typically covers.
Full answer
Can I skip a week of my GLP-1 to make the vial last longer?
Skipping a week is not the same as extending a taper — semaglutide has a ~1-week half-life and tirzepatide is ~5 days, so a skipped week drops your steady-state level below therapeutic range and appetite rebounds sharply. If cost is the driver, the two paths that actually work are the manufacturer savings card (Wegovy/Zepbound) or switching to compounded through a telehealth provider ($99-249/mo). See /guides/lower-glp1-cost for the full menu.
Full answer
How long does compounded semaglutide last in the fridge?
Compounded semaglutide vials are typically stable 28-56 days refrigerated (36-46 °F) after first puncture — check the beyond-use date printed by your compounding pharmacy, which supersedes any general rule. Keep the vial in the interior of the fridge, not the door, and never freeze. If the solution turns cloudy, yellowed, or has visible particles, discard and request a replacement — legitimate 503A pharmacies will replace at no charge.
Full answer
Don't see your question? Send it in — our clinical team answers within 5 business days.
Was this page helpful?